Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C

Status:	Recruiting
Conditions:	Neurology
Therapuetic Areas:	Neurology
Healthy:	No
Age Range:	Any - 120
Updated:	3/16/2019
Start Date:	June 19, 2006
Contact:	Nicole M Farhat, C.R.N.P.
Email:	nicole.farhat@nih.gov
Phone:	(301) 594-1765

This study will evaluate clinical and laboratory tests that might be useful in determining if
an investigational drug can slow the progression of Niemann-Pick Disease, Type C (NPC), a
genetic disorder that results in progressive loss of nervous system function. The study will:
1) look for a clinical or biochemical marker that can be used as a measure of response to
treatment, and 2) define the rate of progression of biochemical marker abnormalities in a
group of NPC patients who will later be invited to enroll in a treatment trial.

Patients of any age with NPC may be eligible for this study. Participants undergo the
following procedures every 6 months during 4- to 5-day admissions at the NIH Clinical Center.

- Medical evaluation, including medical history, physical exam, neurological exam,
neuropsychometric evaluation, and blood and urine tests.

- Lumbar puncture (spinal tap): A sample of cerebrospinal fluid (CSF), the fluid that
bathes the brain and spinal cord, is obtained for study. After administration of a local
anesthetic, a small needle is inserted in the space between the bones in the lower back
where the CSF circulates below the spinal cord. A small amount of fluid is collected
through the needle.

- Eye exam and eye movement study: The pupils of the eye are dilated to examine the
structures of the eyes. For the eye movement study a special contact lens is placed on
the eye and the patient looks at a series of target light spots moving on a screen.

- Hearing tests.

- Electroretinography (in patients who can cooperate with the test) to measure the
function of the retina. Before the test, the patient's pupils are dilated and an
electrode (small silver disk) is taped to the forehead. The patient sits in a dark room
for 30 minutes and then a special contact lens is placed on one eye after it has been
numbed with drops. The contact lens senses small electrical signals generated by the
retina when lights flash. During the ERG recording, the eye is stimulated with flashes
of light projected inside a hollow sphere. After the test, a full eye exam is done and
photographs of the retina are taken.

- Magnetic resonance imaging (MRI): This test uses a magnetic field and radio waves to
produce images of the brain and obtain information about brain chemicals. The patient
lies on a table that can slide in and out of the scanner (a narrow cylinder), wearing
earplugs to muffle loud knocking and thumping sounds that occur during the scanning
process. Patients who cannot remain still in the scanner may be sedated for the test.

- Psychometric testing: Patients complete questionnaires.

- Photographs of the patient may be taken for use in teaching sessions or scientific
presentations or publications, with the patient's consent. Patients may be recognizable,
but are not identified by name.

- Pregnancy test in all female patients over 10 years of age at the beginning of each
admission to the Clinical Center.

Niemann-Pick Tyoe C disease (NPC) is an autosomal recessive, lysosomal storage disorder
characterized by accumulation of cholesterol and gangliosides. NPC is a rare (estimated
prevalence of 1:120,000-150,000) neurodegenerative disorder with a wide clinical spectrum and
a variable age of onset. Classically, children with NPC demonstrate neurological dysfunction
with cerebellar ataxia, dysarthria, seizures, vertical gaze palsy, motor impairment,
dysphagia, psychotic episodes, and progressive dementia. In general, adolescent and adult
onset forms have a more insidious onset and slower progression.

There is no effective treatment for NPC and it is a lethal disorder. A major impediment to
the testing of therapeutic interventions is the lack of well-defined outcome measures. The
purpose of this protocol is to obtain both baseline and rate of progression data on clinical
and biochemical markers that may later be used as an outcome measure in a clinical trial.

- INCLUSION CRITERIA:

All patients with an established diagnosis of NPC (biochemical or molecular) will be
considered for this study.

Both NPC1 and NPC2 patients are eligible.

Patients of any age, sex, or ethnic background will be eligible for this study.

EXCLUSION CRITERIA:

Patients will be excluded if they cannot travel to the NIH because of their medical
condition or are too ill to be cared for at home.

We will exclude NPC patients with rapidly progressive neonatal cholestasis.

Patients will be excluded if they are pregnant (a negative urine pregnancy test will be
required for any menstruating female before participation in this study and at each NIH
Clinical Center admission).

Patients will be excluded from the MRI section of the study if they have:

1. Implanted cardiac pacemaker or autodefibrillators

2. Implanted neural pacemakers

3. Cochlear implants

4. Metallic foreign bodies in the eye or CNS (such as a CNS aneurysmal clip)

5. Any form of implanted wire or metal device that may concentrate radio frequency fields

6. Pregnancy (A negative urine pregnancy test will be required for any menstruating
female before participation in this study)

7. History of an adverse reaction to sedation or anesthesia (if sedation is necessary).

8. They do not meet the safety criteria established by the NIH Clinical Center radiology
department for MRI scanning.

Although priority will be given to patients not on Zavesca, because of the potential
limited number of patients, it will not be an exclusion criterion. Patients on Zavesca may
be excluded from a future therapeutic trial.

We found this trial at

sites

Kennedy Krieger Institute

707 North Broadway
Baltimore, Maryland 21205

443-923-9200